Compare CZR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CZR | PRAX |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | 15500 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.1B |
| IPO Year | 2015 | 2020 |
| Metric | CZR | PRAX |
|---|---|---|
| Price | $29.83 | $350.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $31.92 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 6.8M | 622.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,473,504,000.00 | N/A |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $2.48 | $7,758.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.03 | N/A |
| 52 Week Low | $17.86 | $37.25 |
| 52 Week High | $31.58 | $366.52 |
| Indicator | CZR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 65.30 |
| Support Level | $29.18 | $282.49 |
| Resistance Level | $30.88 | $356.39 |
| Average True Range (ATR) | 0.24 | 19.23 |
| MACD | 0.00 | 10.36 |
| Stochastic Oscillator | 38.79 | 91.82 |
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.